Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Immunol ; 210(12): 1925-1937, 2023 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-37098890

RESUMO

COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette-Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge.


Assuntos
COVID-19 , Mycobacterium bovis , Animais , Camundongos , Vacina BCG/genética , Proteínas Recombinantes de Fusão/genética , SARS-CoV-2 , Vacinas Sintéticas , COVID-19/prevenção & controle , Mycobacterium bovis/genética
2.
PLoS Negl Trop Dis ; 15(1): e0009007, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33465126

RESUMO

The Schistosoma mansoni SmKI-1 protein is composed of two domains: a Kunitz-type serine protease inhibitor motif (KD) and a C-terminus domain with no similarity outside the genera. Our previous work has demonstrated that KD plays an essential role in neutrophil elastase (NE) binding blockage, in neutrophil influx and as a potential anti-inflammatory molecule. In order to enhance NE blocking capacity, we analyzed the KD sequence from a structure-function point of view and designed specific point mutations in order to enhance NE affinity. We substituted the P1 site residue at the reactive site for a leucine (termed RL-KD), given its central role for KD's inhibition to NE. We have also substituted a glutamic acid that strongly interacts with the P1 residue for an alanine, to help KD to be buried on NE S1 site (termed EA-KD). KD and the mutant proteins were evaluated in silico by molecular docking to human NE, expressed in Escherichia coli and tested towards its NE inhibitory activity. Both mutated proteins presented enhanced NE inhibitory activity in vitro and RL-KD presented the best performance. We further tested RL-KD in vivo in an experimental model of monosodium urate (MSU)-induced acute arthritis. RL-KD showed reduced numbers of total cells and neutrophils in the mouse knee cavity when compared to KD. Nevertheless, both RL-KD and KD reduced mice hypernociception in a similar fashion. In summary, our results demonstrated that both mutated proteins showed enhanced NE inhibitory activity in vitro. However, RL-KD had a prominent effect in diminishing inflammatory parameters in vivo.


Assuntos
Leucina/efeitos dos fármacos , Leucina/genética , Mutação Puntual , Proteínas Secretadas Inibidoras de Proteinases/química , Proteínas Secretadas Inibidoras de Proteinases/genética , Proteínas Secretadas Inibidoras de Proteinases/farmacologia , Schistosoma mansoni/genética , Schistosoma mansoni/metabolismo , Animais , Artrite , Leucina/química , Leucina/metabolismo , Elastase de Leucócito/efeitos dos fármacos , Camundongos , Simulação de Acoplamento Molecular , Neutrófilos , Proteínas Secretadas Inibidoras de Proteinases/metabolismo , Proteínas Recombinantes , Relação Estrutura-Atividade , Especificidade por Substrato , Receptor 4 Toll-Like/genética , Transcriptoma
3.
Microbes Infect ; 20(9-10): 606-609, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29355617

RESUMO

Proteins containing a Kunitz domain have the typical serine protease inhibition function ranging from sea anemone to man. Protease inhibitors play major roles in infection, inflammation disorders and cancer. This review discusses the role of serine proteases containing a Kunitz domain in immunomodulation induced by helminth parasites. Helminth parasites are associated with protection from inflammatory conditions. Therefore, interest has raised whether worm parasites or their products hold potential as drugs for treatment of immunological disorders. Finally, we also propose the use of recombinant SmKI-1 from Schistosoma mansoni as a potential therapeutic molecule to treat inflammatory diseases.


Assuntos
Anti-Inflamatórios/metabolismo , Proteínas de Helminto/metabolismo , Inflamação/imunologia , Esquistossomose mansoni/imunologia , Inibidores de Serina Proteinase/metabolismo , Animais , Anti-Inflamatórios/química , Proteínas de Helminto/química , Imunomodulação , Inflamação/terapia , Conformação Proteica , Schistosoma mansoni/química , Schistosoma mansoni/imunologia , Esquistossomose mansoni/terapia , Inibidores de Serina Proteinase/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA